Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants

Lead Sponsor:

Vanderbilt University Medical Center

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Lung Cancer

Eligibility:

All Genders

18-120 years

Brief Summary

RATIONALE: Studying samples of tissue, blood, sputum, and urine from patients with lung cancer and from healthy participants in the laboratory may help doctors learn more about changes that occur in D...

Detailed Description

OBJECTIVES: * To identify new molecular abnormalities specific to the development of squamous cell carcinoma of the lung. * To determine the prevalence of candidate biomarkers in lung cancer progress...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Meets 1 of the following criteria:
  • Known or previously diagnosed lung cancer
  • Suspected lung cancer, including the following:
  • Completely resected stage I lung cancer (with no evidence of metastatic disease) for which patient is at risk for developing secondary disease
  • Suspected of having lung cancer due to clinical symptoms, such as positive sputum cytology, hemoptysis, unresolved pneumonia, persistent cough, and positive x-ray
  • Healthy volunteer
  • PATIENT CHARACTERISTICS:
  • WBC ≥ 2,000/mm³ but ≤ 20,000/mm³
  • Platelet count ≥ 50,000/mm³
  • Not pregnant
  • No uncontrolled hypertension (i.e., systolic blood pressure \> 200 mm Hg, diastolic blood pressure \> 120 mm Hg)
  • No unstable angina
  • No known bleeding disorder
  • No other contraindications for white light bronchoscopic examination
  • No other contraindications for fluorescence examination
  • PRIOR CONCURRENT THERAPY:
  • More than 3 months since prior fluorescent photosensitizing agents (hematoporphyrin derivatives)
  • More than 3 months since prior and no concurrent chemopreventative drugs (e.g., tretinoin)
  • More than 6 months since prior ionizing radiation treatment to the chest
  • More than 6 months since prior systemic cytotoxic chemotherapy
  • No concurrent anticoagulant therapy

Exclusion

    Key Trial Info

    Start Date :

    May 1 2001

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    August 1 2016

    Estimated Enrollment :

    689 Patients enrolled

    Trial Details

    Trial ID

    NCT00899028

    Start Date

    May 1 2001

    End Date

    August 1 2016

    Last Update

    April 20 2017

    Active Locations (4)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (4 locations)

    1

    Vanderbilt-Ingram Cancer Center - Cool Springs

    Nashville, Tennessee, United States, 37064

    2

    Vanderbilt-Ingram Cancer Center at Franklin

    Nashville, Tennessee, United States, 37064

    3

    Veterans Affairs Medical Center - Nashville

    Nashville, Tennessee, United States, 37212

    4

    Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee, United States, 37232-6838